CFU-E
Colony-Forming Unit-Erythroid (CFU-E)[edit]
The Colony-Forming Unit-Erythroid (CFU-E) is a crucial stage in the hematopoietic process, specifically in the development of red blood cells. CFU-E is a progenitor cell that arises from the common myeloid progenitor and is committed to the erythroid lineage. This stage is characterized by its sensitivity to erythropoietin (EPO), a hormone that regulates red blood cell production.
Developmental Pathway[edit]
The development of CFU-E is part of the broader process of erythropoiesis, which is the production of red blood cells. The pathway begins with the hematopoietic stem cell (HSC), which differentiates into a common myeloid progenitor (CMP). From the CMP, the cell further differentiates into a burst-forming unit-erythroid (BFU-E), which eventually gives rise to the CFU-E.
CFU-E cells are highly responsive to erythropoietin, which stimulates their proliferation and differentiation into proerythroblasts. These proerythroblasts then undergo several stages of maturation, eventually becoming mature erythrocytes.
Role of Erythropoietin[edit]
Erythropoietin is a glycoprotein hormone produced primarily by the kidneys in response to low oxygen levels in the blood. It plays a critical role in the survival, proliferation, and differentiation of CFU-E cells. Erythropoietin binds to its receptor on the surface of CFU-E cells, activating signaling pathways that prevent apoptosis and promote cell division and maturation.
Clinical Significance[edit]
The regulation of CFU-E and erythropoiesis is vital for maintaining adequate levels of red blood cells and ensuring proper oxygen transport throughout the body. Disorders in this process can lead to conditions such as anemia, where there is a deficiency of red blood cells, or polycythemia, where there is an excess.
Therapeutically, recombinant erythropoietin is used to treat anemia, particularly in patients with chronic kidney disease or those undergoing chemotherapy, as these conditions can impair the body's natural erythropoietin production.
Related Pages[edit]
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian